Reimbursement Scheme Adhesa®
The health insurer does not fully reimburse Adhesa® 5 mg. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal…
Update Reimbursement Scheme Adempas®
As off May 31st 2023, the reimbursement for Adempas® 0.5 mg and 1.0 mg is now also indicated for the treatment of PAH in pediatric patients aged less than…
Reimbursement Scheme Jardiance® - Chronic Kidney Disease
Arrangement for reimbursement by TerugBetaalRegeling Jardiance® (empagliflozin) 10 mg for patients with chronic kidney disease without type 2…
At Phareso B.V., registered at Professor Bavincklaan 7, 1183 AT Amstelveen, The Netherlands and its Foundations, together trading as Terugbetaalregeling.nl, (“TBR, "we", "us") we respect your…
General information
The pharmacist has dispensed Uptravi® 200, 400, 600, 800 or 1000mcg to the patient. The health insurer will not reimburse the cost of this prescription in full. The…
Reimbursement Scheme Signifor®
The health insurer does not fully reimburse Signifor® 20mg. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal…
Update TerugBetaalRegeling Veltassa®, patiromer 8.4g
From May 1, 2023, the use of Veltassa® 8.4g will be fully reimbursed by the health insurer. For this reason the Reimbursement Scheme of Veltassa®…
Update Reimbursement Scheme Jardiance®
From April 1, 2023, the use of Jardiance® (empagliflozin) in patients with chronic heart failure regardless of ejection fraction (HfrEF, HFmrEF and HFpEF) is…
Update Reimbursement Fludrace®
The existing TBR for Fludrace® 62.50 micrograms has been expanded with the strength 31.25 micrograms. Because the health insurer has not fully reimbursed this…
